Updated on 24 July 2013
While Pioglitazone is currently banned in France, it is sold in various other countries, including the US and the UK, with a warning on the label cautioning against potential risks. In India, about three to four million people are said to have been prescribing Pioglitazone for diabetes.
Immediately after its ban in India, many medical practitioners across the country had argued that there was not much scientific evidence or reported adverse events caused due to the drug.
An expert panel consisting of diabetologists and pharmacologists further had met the Director General Health Services and the Drugs Controller General of India (DCGI) earlier this month to advise him on revoking the suspension on sale of the drug in India.